Apply to trial NCT06799195

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening